GlassScriptPhysician profile
Kevin John Dasher
NPI 1386602712
$11,042.88
in general payments reported to CMS, 2019-2025
42 companies · $4,602 in 2025
The $4,602 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $222 · 2021: $1,041 · 2022: $1,030 · 2023: $1,320 · 2024: $1,994 · 2025: $4,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,042 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,828 · Education: $45.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,042.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,828.00 |
| Education | $45.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,915.43 | 2025 | Austedo Xr |
| Abbvie INC. | $2,566.68 | 2019-2025 | Mavyret, Linzess, Skyrizi |
| Boston Scientific Corporation | $1,128.12 | 2019-2025 | Compliance Endokit, Axios, Wallflex Duodenal |
| Gilead Sciences, INC. | $542.32 | 2019-2025 | |
| Janssen Biotech, INC. | $497.50 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $366.73 | 2019-2025 | Xifaxan, Trulance |
| Ipsen Biopharmaceuticals, INC | $244.45 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $227.96 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $210.73 | 2019-2025 | Ocaliva |
| Endogastric Solutions, INC | $210.43 | 2022-2023 | Esophyx |
| Phathom Pharmaceuticals, INC. | $207.54 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $206.33 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $139.51 | 2024-2025 | Zenpep, Vowst |
| Pfizer INC. | $132.12 | 2019-2025 | |
| Celltrion USA INC. | $115.77 | 2024-2025 | Vegzelma, Zymfentra |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $106.92 | 2021-2023 | |
| Daiichi Sankyo INC. | $101.10 | 2019-2023 | Injectafer |
| Cook Medical LLC | $91.33 | 2022-2025 | Hemospray |
| Madrigal Pharmaceuticals | $88.59 | 2025 | Rezdiffra |
| Ardelyx, INC. | $84.92 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $82.41 | 2019-2024 | Sucraid |
| Merck Sharp & Dohme LLC | $77.64 | 2021-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $77.56 | 2023-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $76.25 | 2023-2024 | Dupixent |
| Ethicon US, LLC | $65.06 | 2021 | |
| Celgene Corporation | $63.17 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $53.90 | 2019-2024 | Eohilia |
| Shionogi INC | $49.11 | 2019 | |
| Redhill Biopharma INC. | $46.43 | 2023 | Talicia, Movantik, Aemcolo |
| Evoke Pharma, INC. | $39.94 | 2025 | |
| Echosens North America, INC. | $39.58 | 2025 | Fibroscan |
| Shield Therapeutics INC | $26.07 | 2023 | Accrufer |
| Albireo Pharma, INC. | $24.91 | 2024 | Iqirvo |
| Ferring Pharmaceuticals INC. | $22.21 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $20.13 | 2021 | |
| Apollo Endosurgery US INC | $18.44 | 2019 | |
| Conmed Corporation | $17.55 | 2023 | Conmed Hemostasis |
| Enterra Medical, INC. | $17.51 | 2023 | |
| Olympus America INC. | $16.29 | 2022 | |
| Alnylam Pharmaceuticals INC. | $12.80 | 2021 | |
| Allergan, INC. | $11.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,808.17 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Dasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.